Identification of LPO and RTN4R as Proteomic Signatures of Pain Persistence: An Exploratory Analysis of the UK Biobank

This exploratory analysis of the UK Biobank identifies Lactoperoxidase (LPO) and Nogo Receptor (RTN4R) as dominant proteomic signatures driving pain persistence, demonstrating that specific molecular pathways related to secretory peroxidase activity and neural repair inhibition are more predictive of chronic pain than broad systemic factors like monocyte counts or testosterone levels.

The Gist

Imagine your body is like a highly sophisticated city. When you get hurt (like a cut or a bruise), it's a bit like a construction accident in that city. Usually, the city has a great emergency response team that comes in, fixes the damage, cleans up the mess, and sends everyone home so life can return to normal. This is acute pain—it's the alarm bell ringing while the repairs are happening.

But for some people, the alarm never stops ringing. The construction crew gets stuck, the traffic never clears, and the "pain" becomes a permanent part of the city's landscape. This is chronic pain.

Scientists have long wondered: Why do some people's bodies fix the problem quickly, while others get stuck in a permanent state of pain?

This new study, using data from over 500,000 people in the UK, tried to find the answer. They looked at two main theories:

1. The "Headcount" Theory: Maybe it's about how many repair workers (immune cells) you have.
2. The "Toolbox" Theory: Maybe it's not about how many workers you have, but what tools they are using and what signals they are sending.

Here is what they found, explained simply:

1. The Old Idea: It's About the "Headcount"

For a long time, researchers thought that if you had more "repair workers" (specifically a type of immune cell called monocytes) and more "healing hormones" (like testosterone), your pain would go away faster.

Think of it like a construction site: "If we just hire more workers, the building will get fixed faster!"

• The Study's Finding: In the big picture, yes, having more testosterone seemed helpful. But when they looked closer at the specific people who failed to heal, the number of workers didn't matter as much as we thought. It wasn't that they didn't have enough workers; it was that the workers were using the wrong tools.

2. The New Discovery: The "Broken Tools" and "Stuck Doors"

The researchers used a high-tech scanner to look at nearly 3,000 different proteins (the chemical tools and signals) in people's blood. They found two specific "culprits" that were much better at predicting who would get stuck in chronic pain than the number of workers was.

Culprit #1: LPO (The "Rusty Hammer")

They found a protein called Lactoperoxidase (LPO).

• The Analogy: Imagine your immune cells are construction workers. LPO is like a rusty, over-enthusiastic hammer. When these workers swing this hammer, they create a lot of "oxidative stress"—basically, they are making a mess while trying to fix the problem.
• The Result: People with high levels of LPO were much more likely to stay in pain. The study showed that the activity of this "rusty hammer" was the real problem, not the number of workers holding it. Once they accounted for LPO, the number of workers (monocytes) stopped being a predictor. It's not about how many workers you have; it's about whether they are swinging a rusty hammer that damages the site.

Culprit #2: RTN4R (The "Do Not Enter" Sign)

They also found a protein called RTN4R (Nogo Receptor).

• The Analogy: Imagine your nerves are like roads that need to be repaved after an accident. RTN4R is like a giant "Do Not Enter" or "Road Closed" sign that gets stuck on the road. It tells the nerves, "Stop trying to heal and repair yourself."
• The Result: High levels of this "Do Not Enter" sign meant the nerves couldn't repair the damage, leaving the pain signals stuck in the "on" position forever.

3. The "Testosterone" Twist

The study also looked at testosterone. Previous research suggested testosterone helps men heal faster.

• The Finding: The study confirmed that testosterone is indeed protective. However, the new discovery suggests testosterone might work by keeping the "rusty hammers" (LPO) down and the "Do Not Enter" signs (RTN4R) off the roads.
• The Takeaway: Testosterone isn't a magic wand that fixes pain directly; it's the manager that ensures the workers use the right tools and don't put up the wrong signs.

The Big Picture: Why This Matters

This study changes how we think about pain.

• Before: We thought, "Do they have enough immune cells? Do they have enough hormones?" (Focusing on the quantity).
• Now: We know we need to ask, "Are their immune cells creating too much oxidative stress? Are their nerves blocked from repairing?" (Focusing on the quality and function).

In simple terms:
If you are stuck in chronic pain, it might not be because your body lacks the people to fix it. It might be because the people you have are using the wrong tools (LPO) and the repair roads are blocked by "Do Not Enter" signs (RTN4R).

This gives doctors a new target. Instead of just trying to boost the number of immune cells, future treatments might focus on:

1. Disarming the "Rusty Hammer" (lowering LPO).
2. Removing the "Do Not Enter" signs (blocking RTN4R).

This could lead to new medicines that help the body finally turn off the pain alarm and let the city return to normal.

Technical Summary

1. Problem Statement

The transition from acute to chronic pain represents a failure of physiological resolution, a process poorly understood at the molecular level. While preclinical research (specifically Sim et al., 2026) suggests that androgen-driven monocyte accumulation facilitates pain resolution in males, translating these findings to human populations has been challenging.

• The Gap: It remains unclear whether systemic proxies of this neuroimmune axis (total monocyte counts, serum testosterone, and plasma IL-10) are independent predictors of pain chronification in humans, or if specific functional molecular signatures drive the persistence of pain.
• The Objective: To identify proteomic drivers of long-term pain persistence and determine if they operate independently of systemic factors like cell counts and hormone levels.

2. Methodology

The study utilized a multi-stage analytical approach using data from the UK Biobank (UKBB) (Application #57245).

• Cohort Definition:

  • Cross-Sectional Analysis: A large cohort ($N = 419,040$) with complete baseline pain data to assess chronic pain prevalence.
  • Longitudinal Persistence Cohort: A specific subset ($N = 3,221$) identified as having acute pain (pain <3 months) at baseline and available follow-up data (mean interval: 1,579 days). The outcome was defined as the failure of pain to resolve (transition to chronic pain >3 months).
  • Proteomic Subsample: A focused subset ($N = 304$) with concurrent Olink proteomic data for neuroimmune analysis.

• Data Sources & Variables:

  • Proteomics: 2,923 serum proteins measured via the Olink Explore 3072 proximity extension assay (PEA) platform.
  • Systemic Biomarkers: Absolute monocyte counts, serum testosterone, and IL-10 levels.
  • Covariates: Age, sex, BMI, smoking status, and C-reactive protein (CRP).

• Statistical Analysis:

  • Screening: High-throughput logistic regression to identify proteins associated with pain chronification, corrected for multiple testing using the Benjamini-Hochberg False Discovery Rate (FDR).
  • Competition Models: Multivariable logistic regression models were constructed to test the independent predictive power of top proteomic hits (LPO and RTN4R) against systemic factors (monocytes and testosterone). All continuous variables were Z-score standardized.
  • Software: Analyses performed in R (v4.3.1).

3. Key Contributions

• Shift from "Volume" to "Function": The study challenges the paradigm that systemic cell quantity (e.g., total monocyte count) drives pain outcomes, proposing instead that specific functional molecular signatures are the primary determinants.
• Identification of Novel Biomarkers: The discovery of Lactoperoxidase (LPO) and Nogo Receptor (RTN4R) as dominant, independent predictors of pain persistence.
• Mechanistic Insight: The demonstration that these proteomic markers "knock out" the statistical significance of systemic monocytes and testosterone, suggesting they are the proximal mediators of the observed biological effects.

4. Key Results

A. Systemic vs. Proteomic Predictors

• Cross-Sectional Findings: Higher testosterone was protective against chronic pain prevalence (OR = 0.988), while higher monocyte counts were associated with increased risk (likely mediated by inflammation/BMI).
• Longitudinal Findings: In the transition model, metabolic factors (BMI, smoking) were dominant predictors. However, when proteomic data was introduced, the picture changed significantly.

B. The Dominance of LPO and RTN4R

• Lactoperoxidase (LPO): Identified as the most significant predictor.
  • Effect Size: Each standard deviation (SD) increase in LPO was associated with a 59% increase in the odds of pain persistence (OR 1.59, 95% CI 1.25–2.07, $p < 0.001$).
  • Competition: When LPO was included in the model, systemic monocyte counts ($p = 0.55$) and testosterone ($p = 0.46$) lost statistical significance.
• Nogo Receptor (RTN4R): Also a significant independent predictor (OR 1.44, $p = 0.002$).
  • Competition: Similar to LPO, inclusion of RTN4R rendered monocytes and testosterone non-significant.

C. Sex and Hormonal Interactions

• No significant interaction was found between sex and testosterone or monocyte counts, suggesting the protective mechanisms operate similarly across sexes, though absolute hormone levels differ.
• The study suggests testosterone may exert its protective effect by modulating these specific proteomic pathways (e.g., suppressing LPO-driven oxidative stress) rather than acting as a direct independent predictor in the presence of these markers.

5. Significance and Implications

• Paradigm Shift: The findings suggest that pain resolution failure is driven by localized molecular precision (oxidative stress and neural repair inhibition) rather than broad systemic inflammation or cell counts.
• Biological Mechanisms:
  • LPO: As a secretory peroxidase, elevated LPO suggests a state of oxidative stress and mucosal barrier dysfunction that prevents pain resolution. It implies that the activity of myeloid cells (producing oxidative mediators) is more critical than their quantity.
  • RTN4R: As an inhibitor of axonal regeneration, its association suggests a structural failure in neural repair, preventing the nervous system from "healing" sensitization.
• Clinical Translation:
  • Biomarkers: LPO and RTN4R are proposed as superior companion diagnostics for identifying patients at risk of chronic pain compared to traditional markers like CRP or monocyte counts.
  • Therapeutic Targets: Future interventions may focus on modulating peroxidase-driven oxidative pathways or overcoming neural repair inhibition (RTN4R) rather than broadly suppressing inflammation.
• Limitations & Context: The authors acknowledge the temporal gap in UK Biobank data (mean 4.3 years) compared to acute trauma studies (e.g., AURORA cohort). They posit that LPO and RTN4R represent a "locked" physiological state of persistence rather than transient acute inflammation markers.

Conclusion: This study provides population-level evidence that the transition to chronic pain is mediated by specific functional proteins (LPO and RTN4R) which supersede systemic hormonal and cellular markers, offering new targets for precision medicine in pain management.